1. P01.047 Improving quality of life in glioma patients: platform for exchange of patients' expertise in TTFields practice. (19th September 2018) Authors: Kessler, A; Jentschke, E; Weiland, J; Dufner, V; Lilla, N; Linsenmann, T; Westermaier, T; Hagemann, C; Ernestus, R; Löhr, M Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii239 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P04.17 Antigen heterogeneity in glioblastoma cell lines, patient-derived cells, and patients' glioblastoma tissue is an obstacle for CAR-T cell therapy development. (9th September 2021) Authors: Dufner, V; Schulz, E; Monoranu, C; Hudecek, M; Ernestus, R; Hagemann, C; Löhr, M; Nerreter, T Journal: Neuro-oncology Issue: Volume 23: Supplement 2 (2021) Page Start: ii21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P06.04.B Efficacy of Podoplanin-CAR-T Cells inex vivo Patient Derived Glioblastoma Organoids. (5th September 2022) Authors: Diener, L; Goedert, N; Schulz, T; Monoranu, C; Ernestus, R; Hagemann, C; Löhr, M; Nerreter, T; Dufner, V Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P11.34.A Pseudoprogression in cases of brain metastases and its neurooncological pitfalls under PD-1 inhibitor therapy in the era of personalized medicine. (5th September 2022) Authors: Schulz, T; Cattaneo, A; Löhr, M; Dufner, V; Monoranu, C; Keßler, A Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗